Healthcare & Pharmaceuticalscategory· January 15, 2025 US bans use of Red No.3 dye in food ... double vision and eye bulging in a late-stage study, sending its shares surging more than 26%.

Biohaven (BHVN) highlighted the success of BHV ... In the four-week Phase 1 study, subcutaneously administered BHV-1300 at a dose of 1000 mg weekly achieved rapid, deep and sustained reductions ...

Polystyrene nanoparticles are widely used in packaging, but their effects on organisms are unclear. Very little was known ...

Dose escalation with BHV-1300 continues in the study and plans to explore deeper reductions to characterize the potential range of targeted IgG lowering possible with Biohaven's MoDE™ technology ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

Topline results from the MDD study are expected in the second half of 2025, and topline data from the focal epilepsy studies (NCT06309966 and NCT06132893) are expected in early 2026. Biohaven ...

Biohaven completed interactions with FDA enabling registrational programs for Parkinson's disease and the prevention of ARIA. Initiate BHV-8000 Phase 2/3 study in Parkinson's disease in 1H 2025.

Based upon the rapid and deep reductions of total IgG observed with subcutaneous BHV-1300, Biohaven reiterates its plans to initiate a Phase 2 study in Graves' disease in mid-2025. Additional ...

A personal finance company recently set out to determine the most "sinful" states in 2025 — and the results show a mix of red and blue states. In a study published on Feb. 24, WalletHub wrote ...